<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="cd20-neg-bnhl-mb-all-vinti">
    <meta name="study:title" content="PB3356 - CD20-negative relapsed/refractory mature B-cell non-Hodgkin lymphomas (B-NHLs) and mature B-cell leukemia in children, adolescents, and young adults: A retrospective review">
    <meta name="study:fileName" content="Abstracts/CD20-NEG-BNHL-MB-ALL-VINTI-PB3356.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Rituximab,Monoclonal Antibody,Chemotherapy,Bispecific antibodies">

    <title>PB3356: CD20-Negative R/R B-NHL/mB-ALL (Vinti) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3356 - CD20-Negative R/R Mature B-Cell Malignancies in Young Patients</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=27)</h4>
                    <p>Children/Young Adults with R/R B-NHLs/mB-ALL. Aim: Evaluate CD20 expression at relapse & its impact.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methods (Retrospective Review)</h4>
                    <p>Data from Italian Centers (past 10 yrs). CD20 status by IHC/flow at relapse. Most had prior Rituximab.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Finding: CD20 Loss at Relapse</h4>
                    <p><span class="highlight-value">40%</span> (11/27) showed CD20 loss at relapse (vs. 100% CD20+ at dx). Most relapses <100 days post-Tx.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Outcome & Conclusion</h4>
                    <p>CD20-loss assoc. with more aggressive disease & worse outcome (7/10 CD20- died vs 7/17 CD20+). Histological re-eval crucial for targeted Tx.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3356 - CD20-negative relapsed/refractory mature B-cell non-Hodgkin lymphomas (B-NHLs) and mature B-cell leukemia in children, adolescents, and young adults: A retrospective review</h1>
            <p class="abstract-sub-header">Luciana Vinti, Jolanda Pianese, Daniela Onofrillo, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3356 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Common pediatric mature B-cell malignancies: Burkitt lymphoma, DLBCL, PMBCL, mature B-ALL (mB-ALL).</li>
                        <li>Rituximab + chemotherapy improved EFS/OS, but prognosis for R/R disease is dismal.</li>
                        <li>Standard reinduction for R/R pediatric B-NHL/mB-ALL is not established.</li>
                        <li>Novel agents (monoclonal/bispecific CD20-CD3 Abs) are in development.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate CD20 expression by immunohistochemistry (IHC) and/or flow cytometry in R/R B-NHLs/mB-ALL in children and young adults, and its potential role in resistance, through an updated retrospective study.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Retrospective review.</li>
                        <li>Patient Population: Children and young adults with R/R B-NHLs/mB-ALL from 12 Italian Centers over the past 10 years.</li>
                        <li>Data Collection: Baseline data, CD20 status at relapse (biopsy/cytological evaluation), treatment, and outcomes.</li>
                        <li>CD20 Expression Analysis: IHC and/or flow cytometry on samples at relapse.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Retrospective Review of CD20 Status in R/R Pediatric B-Cell Malignancies</h3>
                        <div class="schema-enrollment">
                            <strong>Children & Young Adults (N=27)</strong>
                            <span>R/R B-NHLs or mB-ALL</span>
                            <span>(12 Italian Centers, Past 10 Years)</span>
                        </div>
                        <div class="schema-arrow-down">â–¼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Data Collection & Analysis</strong>
                                <span>Baseline characteristics</span>
                                <span>CD20 status at diagnosis (all CD20+)</span>
                                <span>CD20 status at relapse (IHC and/or Flow Cytometry)</span>
                                <span>Prior Rituximab exposure</span>
                                <span>Treatment outcomes post-relapse</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Incidence of CD20 loss at relapse</span>
                           <span>Correlation of CD20 status with clinical features & outcome</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics & CD20 Status (N=27)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age at Diagnosis: 11.4 years (range, 4.1-19.3).</li>
                        <li>Median Age at Relapse: 12.3 years (range, 4.6-21.3).</li>
                        <li>Diagnoses: Burkitt Lymphoma (most common), DLBCL, mB-ALL, PMBCL.</li>
                        <li>Prior Rituximab: 24/27 patients (median 6 infusions).</li>
                        <li>Time to Relapse: <100 days for 20/27 patients (median 1.8 months from last treatment).</li>
                        <li><strong>CD20 Loss at Relapse: 40% (11/27 patients)</strong> by IHC and/or flow cytometry (all were CD20 positive at diagnosis). Biopsy mostly at first relapse (15 pts).</li>
                    </ul>
                     <div class="chart-container my-4">
                        <svg id="cd20LossChart" width="300" height="250"></svg>
                        </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Outcomes Based on CD20 Status at Relapse</h2>
                     <p class="text-sm font-semibold mt-1 mb-1">CD20-Negative Patients (n=10*):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Died of progressive disease: 7.</li>
                        <li>Partial Response (on treatment): 2 (1 Burkitt, 1 DLBCL).</li>
                        <li>Alive and disease-free: 1 (experienced Hodgkin lymphoma as second cancer).</li>
                        <li>(*Abstract mentions 11/27 CD20 loss, then details outcomes for 10 CD20-negative patients. This discrepancy is noted from the source.)</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">CD20-Positive Patients (n=17):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Died: 7.</li>
                        <li>Alive: 10 (6 CR, 4 PR).</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Hematopoietic Stem Cell Transplantation (HSCT):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>7 patients received HSCT (5 allogeneic, 2 autologous).</li>
                        <li>2 of these had CD20-negative relapse.</li>
                        <li>3 patients post-alloHSCT are alive and disease-free.</li>
                    </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Loss of CD20 expression at relapse occurred in 40% of pediatric/young adult patients with R/R B-NHLs/mB-ALL in this retrospective cohort.</li>
                <li>CD20-loss was characterized by a more aggressive disease course and worse outcomes compared to patients who remained CD20-positive at relapse.</li>
                <li>Given the potential benefit of CD20-targeted therapies (monoclonal or bispecific antibodies), these findings underscore the importance of histological re-evaluation, including CD20 status assessment, whenever possible at relapse to guide appropriate targeted therapy selection.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>Abs, Antibodies; ALL, Acute Lymphoblastic Leukemia; ASCT, Autologous Stem Cell Transplant; B-NHL, B-cell Non-Hodgkin Lymphoma; CD, Cluster of Differentiation; CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; EFS, Event-Free Survival; HSCT, Hematopoietic Stem Cell Transplantation; IELSG, International Extranodal Lymphoma Study Group; IHC, Immunohistochemistry; mB-ALL, Mature B-cell Acute Lymphoblastic Leukemia; MTX, Methotrexate; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; OS, Overall Survival; PCNS-DLBCL, Primary Central Nervous System Diffuse Large B-Cell Lymphoma; PMBCL, Primary Mediastinal B-Cell Lymphoma; PR, Partial Response; Pts, Patients; R/R, Relapsed or Refractory; Tx, Treatment; WBC, White Blood Cell.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Zhao X, Liu Z. High-dose Thiotepa combined with Rituximab and Pomalidomide is a perfect alternative chemotherapy regimen for relapsed/refractory primary central nervous system diffuse large B cell lymphoma. Abstract #PB3233 presented at European Haematology Association (EHA) June 12â€“15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3233 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
    function drawCd20LossChart(containerId) {
        const chartTitle = "CD20 Status at Relapse (N=27)";
        // Data: 11/27 (40%) CD20 loss, so 16/27 (60%) CD20 positive
        const chartData = [
            { status: "CD20 Loss", value: 40.7, count: 11, color: "var(--sobi-red)" }, // 11/27 is approx 40.7%
            { status: "CD20 Positive", value: 59.3, count: 16, color: "var(--sobi-teal)" } // 16/27 is approx 59.3%
        ];

        const svg = d3.select(containerId);
        svg.selectAll("*").remove(); // Clear previous chart

        let containerWidth = 300;
        const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
        if (chartWrapper) {
            containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.90, 250);
        }
        
        const svgWidth = containerWidth;
        const svgHeight = +svg.attr("height");
        const margin = { top: 40, right: 20, bottom: 20, left: 20 };
        const radius = Math.min(svgWidth - margin.left - margin.right, svgHeight - margin.top - margin.bottom) / 2;
        
        const g = svg.append("g")
            .attr("transform", `translate(${(svgWidth / 2)}, ${(svgHeight / 2) + margin.top/2})`);

        const pie = d3.pie().sort(null).value(d => d.value);
        const path = d3.arc().outerRadius(radius - 10).innerRadius(0);
        const label = d3.arc().outerRadius(radius - 40).innerRadius(radius - 40);

        const arcs = g.selectAll(".arc")
            .data(pie(chartData))
            .enter().append("g")
            .attr("class", "arc");

        arcs.append("path")
            .attr("d", path)
            .attr("fill", d => d.data.color);

        arcs.append("text")
            .attr("transform", d => `translate(${label.centroid(d)})`)
            .attr("dy", "0.35em")
            .style("font-size", "10px")
            .style("fill", "white")
            .style("text-anchor", "middle")
            .text(d => `${d.data.status}\n${d.data.value.toFixed(1)}% (${d.data.count})`);
        
        svg.append("text")
            .attr("x", svgWidth / 2)
            .attr("y", margin.top / 2)
            .attr("text-anchor", "middle")
            .style("font-size", "13px")
            .style("font-weight", "600")
            .style("fill", "var(--sobi-dark-blue)")
            .text(chartTitle);
    }
    
    function debounce(func, wait) {
        let timeout;
        return function executedFunction(...args) {
            const later = () => { clearTimeout(timeout); func(...args); };
            clearTimeout(timeout);
            timeout = setTimeout(later, wait);
        };
    };

    const debouncedDrawCd20Chart = debounce(() => drawCd20LossChart("#cd20LossChart"), 250);
    
    window.addEventListener('resize', debouncedDrawCd20Chart);
    document.addEventListener('DOMContentLoaded', debouncedDrawCd20Chart);
    if (document.readyState === "complete" || document.readyState === "interactive") {
         setTimeout(debouncedDrawCd20Chart, 0); 
    }
    </script>
</body>
</html>
